New article in BioStock: CombiGene comments on recent progress
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 CombiGene has recently raised more than SEK 25 million through two successful warrants, which were excercised at 98.4 percent. At the same time, CombiGene's two gene therapy projects...
read moreOn November 24, CEO Jan Nilsson presented CombiGene at Aktieportföljen Live
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 On November 24, CEO Jan Nilsson presented CombiGene's development during the year and plans for the future at Aktieportföljen Live. If you didn't have the opportunity to follow the...
read moreBioStock: CombiGene signs agreement, major shareholders and insiders sign shares
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 CombiGene epilepsy project CG01 continues to advance its positions. At the same time, insiders are signing shares in the company. Read BioStock's article here >> About...
read moreBioStock: CombiGene on the first in vivo study in the lipodystrophy project CGT2
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 CombiGene’s lipodystrophy project CGT2 is developing according to plan and has recently started the first in vivo studies. Read the interview in BioStock where CombiGene's CEO Jan Nilsson...
read moreInterview in BioStock ” CombiGene comments the final preclinical steps”
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 "The gene therapy company CombiGene, which is developing a new treatment for drug-resistant focal epilepsy, is planning to focus on the final preclinical studies next year and then begin...
read moreDen 20 oktober presenterade Karin Agerman, Chief Research & Development Officer på CombiGene på ATMP Swedens webinar Manufacturing of Gene Therapy Products in Sweden
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 On October 20, Karin Agerman, Chief Research & Development Officer at CombiGene presented on ATMP Sweden's webinar Manufacturing of Gene Therapy Products in Sweden. Karin gave her...
read moreOn October 19, CEO Jan Nilsson and Chief Research & Development Officer Karin Agerman presented CombiGene at Aktiespararna
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 On October 19, CEO Jan Nilsson and Chief Research & Development Officer Karin Agerman presented CombiGene at Aktiespararna's digital event. If you didn't have the opportunity to...
read moreBiostock has published an article on the development of advanced medical therapies in Sweden
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 On October 19, Biostock published an article on the development of advanced medical therapies in Sweden and how Sweden compares to an international comparison. The article mentions...
read moreCombiGene’s new Chairman of the Board talks about the future visions for the company
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 This is an article from Ingeneious number 3 2020.Read the whole Ingeneious here >> At the gene therapy company CombiGene’s Annual General Meeting in June, Bert Junno was elected as...
read moreNew article about CombiGene in Biostock
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 Biostock summarizes the latest news from CombiGene and talks to CEO Jan Nilsson about the importance of the many milestones and the continued plan for the epilepsy project CG01....
read moreDavid Woldbye, one of CombiGene’s scientific founders, talks about gene therapy in Danish pod
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 Associate Professor David Woldbye, one of CombiGene's scientific founders, participates in a podcast arranged by Danish Ugeskrift for Læger. If you understand Danish, click on the link....
read moreCombiGene Chairman Bert Junno interviewed in BioStock
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 CombiGene's Chairman of the Board Bert Junno is interviewed about what attracted him to CombiGene, how he sees the company’s strategy and future and upcoming milestones. Read the...
read moreInterview with CEO Jan Nilsson
Analysguiden – on CombiGenes progress with CG01 (ONLY IN SWEDISH)
Aktiedagen in Stockholm – Company Presentation (ONLY IN SWEDISH)
About CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.